"text","uuid:ID","description","label","name","id","instanceType"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","be66366f-6981-4e26-bd72-a8749b1e906b","Main objective","","OBJ1","Objective_1","Objective"
"To document the safety profile of the xanomeline TTS.","48a84a9f-f0e8-476a-bc97-cf3087ea58f7","Safety","","OBJ2","Objective_2","Objective"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","36777230-cf6c-4669-8e1d-021a6fe046d4","Behaviour","","OBJ3","Objective_3","Objective"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","960d283c-392c-419b-9b93-76eb6e609ae8","","","OBJ4","Objective_4","Objective"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","53adfb00-6035-4b9b-8a68-d41da4a83b11","","","OBJ5","Objective_5","Objective"
"To assess the treatment response as a function of Apo E genotype.","ceba36d8-8619-4d76-aca9-35965bb218b8","","","OBJ6","Objective_6","Objective"
